{
    "symbol": "CRMD",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-12 20:45:26",
    "content": "  These statements are subject to certain risks and uncertainties and include, but are not limited to, any of the following: any statements other than statements of historical fact, regarding management\u2019s expectations, beliefs, goals and plans about the company\u2019s prospects, including its clinical development program, manufacturing activities and marketing approval for DefenCath in the U.S. and other product candidates; future financial position; future revenues and projected costs; potential market acceptance of DefenCath, Neutrolin and other product candidates. More specifically, forward-looking statements include any statements about our clinical development plans and the submission and timing, cost, progress, results, estimates and interpretations thereof; projections as to the company\u2019s future capital raising and spending and cash position; expectations as to the timing and nature of anticipated regulatory actions; possible product licensing, business development or other transactions; any commercial plans and expectations; market projections for our product candidates; and expectations as to manufacturing and product component costs."
}